GENMAB A/S · Drugmakers

GMAB

Low riskNext report: Not enough history

The short version

A company. Institutions are adding.

No insider buying or selling in the last 30 days
Institutions added 25% to their holdings in the quarter ending June 2026 (148 bought, 130 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$44.69+2.1% that day

From GMAB's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

Price chart by TradingView.

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Last 7 days vs normal

48/ 100

SEC filings of any kind. 50 means a normal week.

Accumulating+25.0%

Institutions added 25.0% to their holdings. 148 bought, 130 sold. 3 quarters of net buying in a row.

Shares held by institutions102.3M

Sep '24Jun '26

From SEC filings

Last 0

Next reportNot enough history

Offerings 6 months, flags 12 months, holders 90 days

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Straight from SEC EDGAR

Source: SEC EDGAR filings. For informational purposes. Not investment advice.